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Budget impact analyses (BIA) have taken a back seat to
cost-effectiveness analysis (CEA) in economic evalua-
tion over the years. If CEAwas thewell-born and highly
regarded member of the family, BIA was the slightly
disreputable one, hanging around with a somewhat
suspicious crowd of health-caremanagers, bureaucrats,
budget ofﬁcials, and other silo dwellers. There is no
listing at all for “budget impact analyses” in the index
of the US Panel on Cost-Effectiveness [1]. Other refer-
ence standards, including the well-known work by
Drummond et al., give BIAs scant attention [2].
Reasons for its “dissing” are not hard to under-
stand. Cost-effectiveness analyses are rooted in eco-
nomic theory. They can help guide resource allocation
decisions in a rational and consistent fashion. CEAs
can aid policymakers as they attempt to optimize
population health subject to resource constraints.
Other forms of economic evaluation, such as cost-
beneﬁt analyses, in which beneﬁts and costs are mon-
etized, also yield a decision rule and have a strong
basis in welfare economics. Even cost-minimization
and cost-consequences analyses speak to the cost and
beneﬁt sides of the equation.
In contrast, BIA say nothing explicitly about health
beneﬁts. There is no optimization, no decision rule, no
calculation of value, and no grounding in economic
theory. They simply quantify the ﬁnancial conse-
quences of using health-care services (though they may
consider beneﬁts indirectly to the extent they capture
cost offsets).
Yet, BIA have stubbornly refused to fade away.
Indeed, payers worldwide keep demanding them. The
reasons for the popularity are also not hard to fathom.
Unlike CEAs, BIA speak to affordability, the chief
concern of health managers everywhere. Like any
shopper on a spree, the payer has a real budget con-
straint and worries that he could go broke buying all of
the items purporting to deliver good value for money.
Abstractions like cost per QALY calculations, though
they provide a useful guide to value, have never
addressed the manager’s overarching ﬁscal problem.
To date, however, BIAs have had few journal
articles devoted to their use. Moreover, they have not
received the formal guideline treatment that CEA has
enjoyed. Thus an ISPOR Task Force Report on the
topic is a welcome addition [3].
As the Report argues, a comprehensive assessment
of a new health-care intervention at time of launch can
beneﬁt from both CEA and BIA. At least in some
respects, the two approaches can be viewed as comple-
mentary. CEAs evaluate costs and outcomes associated
with health-care strategies and can be used to guide
coverage or reimbursement decisions. BIAs are used, as
the Report notes, for budget planning, for forecasting,
and for computing the impact of a health technology
on health insurance premiums. BIAs can be helpful in
estimating the ﬁnancial consequences of adoption and
diffusion and in predicting how a change in mix of
drugs versus other therapies will impact the trajectory
of health spending on a condition.
The publication of this Task Force Report will help
legitimize the practice. The Task Force has performed
its job well and delivered a balanced and thoughtful
statement. The call for standards and rigor should help
strengthen the ﬁeld.
Importantly, there is a central focus on the practical
needs of the decision-maker, which sets it apart from
most reports on CEAs. The recommended perspective
is that of the budget holder. The Report notes that the
drawing of budget boundaries is a highly local exer-
cise, and that the speciﬁc set of assumptions of interest
should reﬂect the decision-maker rather than a “refer-
ence case.” The Task Force highlights the fact that
analyses should include data that reﬂect the size, char-
acteristics, and symptoms of the population at hand, as
well as the current and new treatment mix. The Report
emphasizes that where possible BIAs should incor-
porate decision-makers’ own populations for other
parameter estimates.
There are some important qualiﬁers here as well, for
example, that the purpose of BIAs is not to produce
exact estimates but to provide a valid computing
framework on possible budget consequences. The
Report also usefully recommends “that the analyst use
the simplest design that will generate credible and
transparent estimates,” a kind of Occam’s razor for
the ﬁeld. There is also useful guidance for the reporting
of analyses.
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One only wishes the Report had gone further in a
few respects. Additional discussion about how BIA are
being used—and should be used—would have been
helpful. One would have appreciated a worked
example, especially for BIAs that attempt to measure
cost-offsets associated with a new drug, rather than a
mere quantiﬁcation of the ﬁnancial consequences of
uptake. In fairness, this would have been a consider-
able undertaking and probably beyond the scope of
any task force purview, but this kind of illustrative
example was used to great effect by the Panel on Cost-
Effectiveness and is something for ISPOR to consider
for a future project.
One also would have liked more support for the
basic assertion that BIAs is an “essential” part of a
comprehensive economic assessment of medical tech-
nology. The Report notes that a technology could
be efﬁcient but not affordable, and that “in such
instances, there is, unfortunately, no current scientiﬁc
guidance on how to resolve this dilemma.” More com-
mentary on this fundamental question, as well as some
illustrative examples and discussion of a future
research agenda would have been helpful. Also, the
Report emphasizes that models must meet the needs of
decision-makers but this begs many questions about
what decision-makers really want and how anyone is
to know.
A ﬁnal note: it did occur to this reviewer that budget
impact analyses have the unfortunate acronym
“BIAS.” One assumes that that is an unhappy coinci-
dence but it does provoke a point: there is concern as
always about hidden and optimistic assumptions. The
larger wonder, however, is why the drug industry is
asked to do the work that health plans should be doing
themselves.
These remarks should not detract from the good
work of the group. ISPOR Task Force reports have
earned a place as well-cited products that help codify
and clarify important issues for the ﬁeld, from the role
of modeling to the use of economic evaluation along-
side randomized clinical trials [4,5]. They serve as a
focal point for reference and further debate. The Task
Force Report on Budget Impact Analysis clearly
follows in this tradition.
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